Fmoc-11-氨基十一酸 | 88574-07-6

• 物质功能分类: 生物化工 - 生化试剂 - 氨基酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: Fmoc-11-氨基十一酸
• 中文别名: 11-(Fmoc-氨基)十一酸；11-(FMOC-氨基)十一酸
• 英文名称: 11-(9-fluorenylmethyloxycarbonylamino)undecanoic acid
• 英文别名: Fmoc-11-aminoundecanoic acid；Fmoc-11-Aun-OH；Fmoc-Aun-OH；Fmoc-11AUA；Fmoc-AUA；11-(9H-fluoren-9-ylmethoxycarbonylamino)-undecanoic acid；11-(9H-fluoren-9-ylmethoxycarbonylamino)undecanoic acid
• CAS: 88574-07-6
• 化学式: C₂₆H₃₃NO₄
• 分子量: 423.552
• InChiKey: IMEVDILDSCXKJW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  31
• 可旋转键数：
  14
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• 海关编码：
  2924299090
• WGK Germany：
  3
• 危险标志：
  GHS07
• 危险性描述：
  H315,H319,H335
• 危险性防范说明：
  P261,P305 + P351 + P338
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Fmoc-11-aminoundecanoic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Fmoc-11-aminoundecanoic acid
CAS number: 88574-07-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C26H33NO4
Molecular weight: 423.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  Fmoc-11-氨基十一酸 在 4-二甲氨基吡啶 、 2,4,6-三氯苯甲酰氯 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 二乙胺 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 48.0h， 生成
  参考文献：
  名称：

  新型麦考酚酸与腺苷衍生物的合成及其抗增殖活性。

  摘要：

  合成了新的霉酚酸（MPA）和腺苷衍生物的共轭物，并将其评估为来自健康供体的Jurkat细胞系和外周血单核细胞（PBMC）上的潜在免疫抑制剂。与MPA相比，发现所有化合物均对Jurkat细胞系更具活性。将抗增殖活性与MPA和腺苷在2'，3'- O-异亚丙基保护的和具有游离羟基的形式中进行比较。还根据选择性指数（定义为SI = IC 50 / EC 50）讨论了所得结果。

  DOI：

  10.1080/10286020.2018.1451521
• 作为产物：
  描述：

  benzyl 11-(9-fluorenylmethyloxycarbonylamino)undecanoate 在 palladium on activated charcoal 氢气 作用下， 以 四氢呋喃 为溶剂， 以88%的产率得到Fmoc-11-氨基十一酸
  参考文献：
  名称：

  肽序列中的间隔分子：掺入心钠素的类似物

  摘要：

  在本研究中，使用固相合成设计了10种修饰的人心钠素（hANF）类似物。这是通过在合成的每个类似物中在hANF的环状部分内用八肽序列替换“烷基或乙二醇”间隔基来进行的。非天然氨基酸间隔物（1b）和（2d）已经使用溶液化学合成。使用固相合成组装，将后面的间隔子成功地掺入肽结构中。在如此制备的十个类似物中，两个被烷基间隔基取代氨基酸残基Gly 15至Gly 22和Arg 14至Leu 21。依次给出4a和4b。在后一种类似物（4a，4b）的纯化过程中，遇到了其严重溶解性的问题。使用HPLC成功合成并纯化了八个乙二醇间隔的类似物（5a-5h）。（5a-5h）的结构由原子轰击质谱（FAB MS）中存在的质量离子峰和NMR证实。在体内测试了后者的类似物结合作为激动剂或拮抗剂的特定hANF受体的能力。生物学结果表明，这些类似物（5a-5h）均没有活性。

  DOI：

  10.1016/s0040-4020(97)00397-9

文献信息

• Solution- and solid-phase synthesis and anti-HIV activity of maslinic acid derivatives containing amino acids and peptides
  作者：Andres Parra、Francisco Rivas、Pilar E. Lopez、Andres Garcia-Granados、Antonio Martinez、Fernando Albericio、Nieves Marquez、Eduardo Muñoz

  DOI：10.1016/j.bmc.2008.12.041

  日期：2009.2

  Maslinic acid (1) has been coupled at C-28 with several α- and ω-amino acids by using solution- and solid-phase synthetic procedures. Twelve derivatives (2–13) with a single amino acid residue were prepared in solution phase, whereas a dipeptide (14), a tripeptide (15), and a series of conjugate dipeptides (16–24) were synthesized in solid phase. The anti-HIV activity of these compounds was assessed

  通过使用溶液和固相合成方法，山酸（1）在C-28处与几种α-和ω-氨基酸偶联。十二衍生物（2 - 13）与单一的氨基酸残基在溶液相中制备，而二肽（14），三肽（15），和一系列共轭二肽（16 - 24）在固相合成。在携带荧光素酶基因作为报告基因的病毒克隆感染的MT-2细胞上评估了这些化合物的抗HIV活性。虽然在山梨酸中（1）同时具有细胞毒性和抗病毒活性，但只有衍生物13和24 具有抗HIV-1活性，因此代表了一类新型的抗HIV-1化合物。
• [EN] NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS<br/>[FR] NOUVELLES AMIDINES DE THIOPHENE, COMPOSITIONS DE CES AMIDINES ET PROCEDE POUR TRAITER DES MALADIES ET DES ETATS MEDIES PAR LE COMPLEMENT
  申请人：DIMENSIONAL PHARM INC

  公开号：WO2003099805A1

  公开（公告）日：2003-12-04

  Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula (I) or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4 and R7 are defined in the specification, Z is SO or SO2, and Ar is an aromatic or heteroaromatic group as defined herein.

  揭示了一种治疗急性或慢性疾病症状的方法，该方法通过补体级联的经典途径介导，包括向需要此类治疗的哺乳动物施用化合物I的治疗有效量或其溶剂化合物、水合物或药用可接受盐；其中规范中定义了R1、R2、R3、R4和R7，Z为SO或SO2，Ar为本规范中定义的芳香族或杂环芳基。
• Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US20040009995A1

  公开（公告）日：2004-01-15

  Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I 1 or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R 1 , R 2 , R 3 , R 4 and R 7 are defined in the specification, Z is SO or SO 2 , and Ar is an aromatic or heteroaromatic group as defined herein.

  揭示了一种治疗急性或慢性疾病症状的方法，该方法通过补体级联的经典途径介导，包括向需要此类治疗的哺乳动物施用公式I的化合物的治疗有效量或其溶剂化合物、水合物或药用可接受盐；其中在规范中定义了R1、R2、R3、R4和R7，Z为SO或SO2，Ar为本文中定义的芳香族或杂环芳基。
• [EN] MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS<br/>[FR] PEPTIDES MACROCYCLIQUES UTILES COMME IMMUNOMOLDULATEURS
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2016077518A1

  公开（公告）日：2016-05-19

  The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

  本公开提供了一些免疫调节剂化合物，因此对于改善各种疾病，包括癌症和传染病，具有用处。
• ATP-phosphopeptide conjugates as inhibitors of Src tyrosine kinases
  作者：Nguyen-Hai Nam、Sungsoo Lee、Guofeng Ye、Gongqin Sun、Keykavous Parang

  DOI：10.1016/j.bmc.2004.08.043

  日期：2004.11

  A number of Src SH2 domain inhibitors enhance the kinase catalytic activity by switching the closed inactive to the open active conformation. ATP-phosphopeptide conjugates were designed and synthesized as Src tyrosine kinase inhibitors based on a tetrapeptide sequence pTyr-Glu-Glu-Ile (pYEEI) and ATP to block the SH2 domain signaling and substrate phosphorylation by ATP, respectively. In general, ATP-phosphopeptide

  许多Src SH2域抑制剂可通过将封闭的非活性构象切换为开放的活性构象来增强激酶的催化活性。基于四肽序列pTyr-Glu-Glu-Ile（pYEEI）和ATP，设计并合成了ATP-磷酸肽共轭物作为Src酪氨酸激酶抑制剂，以分别阻断SH2结构域信号传导和ATP底物磷酸化。通常，相对于具有短或长接头的其他ATP-磷酸肽缀合物，具有最佳接头（例如化合物5和7，K（i）= 1.7-2.6 microM）的ATP-磷酸肽缀合物显示出更高的对ATP结合位点的结合亲和力，1-4和6（K（i）= 10.1-16.1 microM）和ATP（K（m）= 74 microM）。